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Purpose: Breast and chest wall irradiation (RT) increase the risk 
of cardiac death. This increased risk is presumed to be a result 
of the incidental exposure of the heart to radiation. International 
guidelines (“QUANTEC”) state that for partial heart irradiation a 
“V25Gy < 10% (2 Gy/fraction) will be associated with a < 1% 
probability of cardiac mortality” in long-term follow up after 
radiotherapy. We therefore set out to establish whether or not 
women who died of cardiac disease within 10 years of breast or 
chest wall radiotherapy had radiotherapy plans that violated 
these guidelines. We also assessed the maximum dose of 
radiation delivered to the left anterior descending (LAD) 
coronary artery and cardiac volume parameters in these patients 
on the assumption that the LAD is the critical structure in most 
cardiac events related to RT. 
Methods and Materials: A provincial database was used to 
identify all women < 80 years of age diagnosed with early stage 
breast cancer who were treated with adjuvant RT to the breast 
or chest wall between 2002 and 2006. The heart and LAD were 
retrospectively delineated using a peer reviewed cardiac atlas. 
A 1 cm radial margin was placed around the LAD to create a PRV. 
For each dose plan, DVH’s for the heart and LAD were calculated 
and the V25 compared to the current QUANTEC guidelines.  
Results: Between RT start and June 2015, 76 patients died of a 
cardiovascular event after breast or chest wall RT. Forty-two of 
these patients received left-sided irradiation, and 34 right-sided 
irradiation. For the left sided cases, median time from diagnosis 
to death was 6.7 years, Later cardiac deaths (> 9 years after 
diagnosis) were more common for left-sided cases when 
compared to right-sided cases (38% versus 24%). Radiotherapy 
plans were available for 31 of the left-sided cases. Eleven cases 
were treated without CT planning. Nineteen patients received 
radiation doses of 40-42.56 Gy over 16 fractions, and 12 patients 
doses of 45-50.4 Gy over 25-28 fractions. The heart V25 did not 
exceed 10% in any of our 31 left sided cases. Equivalent doses in 
2 Gy fractions (EQD2) were calculated from the DVH using α/ β 
2Gy. The average maximum heart dose was 35.7 Gy (SD 16.3). 
The average maximum dose was 25.6 Gy (SD 19.8) to the LAD and 
40.6 Gy (SD 16) to the LAD PRV. 
Conclusions: This study has shown that the QUANTEC guidelines 
were not violated in our cohort of patients that died of cardiac 
disease after left-sided breast RT. As only 38% of patients died 
later than nine years after radiotherapy it may be that pre-
existing cardiac risk factors were a dominant factor for cardiac 
death as opposed to effect of RT. It remains unclear as to the 
exact mechanism of increased cardiac mortality as a result of 
RT, but radiation to the LAD may be more important than the 
heart V25 in predicting cardiac mortality. 
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Purpose: Accurate delineation of the lumpectomy cavity is 
important for cavity boost and partial breast irradiation. 
Previous computed tomography (CT) studies showed significant 
uncertainty in cavity delineation, with conformity indices 
between 0.31-0.76. Although magnetic resonance (MR) imaging 
has better soft tissue contrast than CT, previous studies have 
reported contradictory results on improvements in inter-
observer variability or cavity visualization scores with MR. We 
investigated the inter-observer variability in cavity delineation 
using MR compared to CT at baseline and quantified the change 
in cavity volume between pre-treatment and end-of-treatment 
MR for patients undergoing whole breast radiotherapy (WBRT).  
Methods and Materials: Forty-eight patients with breast cancer 
planned for WBRT underwent CT and MR (T1, T1 fat-suppression 
(T1fs) and T2) simulation in the supine treatment position prior 
to radiotherapy, and MR (T1, T1fs and T2) at the end of 
treatment in the same position. MR images were acquired at 3T 
on inhale breath hold using T1 (19s), T1fs (19s) and T2 (1 min 21s 
with 16s per breath). Two observers delineated the cavity on the 
CT and all MR sequences and assigned cavity visualization scores 
to the images. The primary endpoint was inter-observer 
variability, measured using the conformity index (ratio between 
common and union volumes of a pair of contours by observers). 
Cavity visualization scores and conformity indices from CT, T1, 
T1fs and T2 were compared using the repeated-measures 
analysis of variance (ANOVA) test; differences were determined 
using the Tukey post hoc test when the p value from the ANOVA 
test was < 0.05. 
Results: The mean cavity visualization scores at baseline were 
3.14 (CT), 3.26 (T1), 3.41 (T1fs) and 3.58 (T2). The mean 
conformity indices were 0.65, 0.65, 0.72 and 0.68, respectively. 
T1fs and T2 MRI sequences (but not T1) improved the cavity 
visualization score and conformity index compared to CT (all p < 
0.01). There were no significant differences in cavity 
visualization scores or conformity indices between T1fs and T2. 
At the end of treatment, there were no significant differences in 
mean cavity visualization scores among T1, T1fs and T2 
sequences (3.15, 3.29 and 3.31, respectively; p = 0.20). The 
mean conformity indices for these T1, T1fs and T2 scans were 
0.64, 0.72 and 0.66, respectively; the conformity index for T1fs 
was significantly higher than T1 and T2 (p < 0.01). The mean 
cavity volume on T1 and T1fs sequences, decreased from 18cc at 
baseline to 13cc at the end of treatment, and from 17cc to 11cc 
on T2 (p < 0.01).  
Conclusions: T1fs reduced inter-observer variability on both pre- 
and end-of-treatment scans, and measured a reduction in cavity 
volume during WBRT. This rapid sequence can be easily used for 
adaptive boost or partial breast irradiation, especially on MR 
linear accelerators. 
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Purpose: The question if old patients with low-risk breast cancer 
and tamoxifen require adjuvant radiotherapy after breast 
conserving surgery is still under debate. The results of five 
randomized trials are now available. 
Methods and Materials: 3766 older patients with early stage 
breast cancer and tamoxifen were investigated if they needed 
radiation therapy after breast conserving therapy. Published 
hazard ratios and hazard ratios extracted from available survival 
curves for overall survival (OS) and progression free survival (PFS) 
were basis of our meta-analysis. Meta-analysis of the effect sizes 
on PFS was performed using a random effects model based on 
parameter estimates of log hazard ratios in Cox models and their 
standard errors. Furthermore overall survival was examined.  
Results: Additional radiation therapy with tamoxifen did result 
in an improvement of local relapse (Hazard Ratio: 6.8, 95% 
confidence limits 4.23-10.93, p = 2.4E-15).There was no 
significant difference for overall survival. 
Conclusions: Additional radiation therapy with tamoxifen does 
improve local relapse in breast cancer patients but not for 
overall survival. 
 
